Grosset, D.G. et al. 2014. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases. Journal of Rehabilitation Medicine. 47, 2 (Oct. 2014), 183–186. DOI:https://doi.org/10.2340/16501977-1895.